As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Novo Nordisk's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

Novo Nordisk A/S faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy. Learn more ...

Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy ...

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

Eli Lilly & Co. and Novo Nordisk A/S plan to start selling their popular obesity shots to employers through a new approach ...